Quantitative liver proteomics identifies FGF19 targets that couple metabolism and proliferation.

Fibroblast growth factor 19 (FGF19) is a gut-derived peptide hormone that is produced following activation of Farnesoid X Receptor (FXR). FGF19 is secreted and signals to the liver, where it contributes to the homeostasis of bile acid (BA), lipid and carbohydrate metabolism. FGF19 is a promising the...

Full description

Bibliographic Details
Main Authors: Vittoria Massafra, Alexandra Milona, Harmjan R Vos, Boudewijn M T Burgering, Saskia W C van Mil
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0171185&type=printable
_version_ 1826579384777048064
author Vittoria Massafra
Alexandra Milona
Harmjan R Vos
Boudewijn M T Burgering
Saskia W C van Mil
author_facet Vittoria Massafra
Alexandra Milona
Harmjan R Vos
Boudewijn M T Burgering
Saskia W C van Mil
author_sort Vittoria Massafra
collection DOAJ
description Fibroblast growth factor 19 (FGF19) is a gut-derived peptide hormone that is produced following activation of Farnesoid X Receptor (FXR). FGF19 is secreted and signals to the liver, where it contributes to the homeostasis of bile acid (BA), lipid and carbohydrate metabolism. FGF19 is a promising therapeutic target for the metabolic syndrome and cholestatic diseases, but enthusiasm for its use has been tempered by FGF19-mediated induction of proliferation and hepatocellular carcinoma. To inform future rational design of FGF19-variants, we have conducted temporal quantitative proteomic and gene expression analyses to identify FGF19-targets related to metabolism and proliferation. Mice were fasted for 16 hours, and injected with human FGF19 (1 mg/kg body weight) or vehicle. Liver protein extracts (containing "light" lysine) were mixed 1:1 with a spike-in protein extract from 13C6-lysine metabolically labelled mouse liver (containing "heavy" lysine) and analysed by LC-MS/MS. Our analyses provide a resource of FGF19 target proteins in the liver. 189 proteins were upregulated (≥ 1.5 folds) and 73 proteins were downregulated (≤ -1.5 folds) by FGF19. FGF19 treatment decreased the expression of proteins involved in fatty acid (FA) synthesis, i.e., Fabp5, Scd1, and Acsl3 and increased the expression of Acox1, involved in FA oxidation. As expected, FGF19 increased the expression of proteins known to drive proliferation (i.e., Tgfbi, Vcam1, Anxa2 and Hdlbp). Importantly, many of the FGF19 targets (i.e., Pdk4, Apoa4, Fas and Stat3) have a dual function in both metabolism and cell proliferation. Therefore, our findings challenge the development of FGF19-variants that fully uncouple metabolic benefit from mitogenic potential.
first_indexed 2024-12-10T04:24:18Z
format Article
id doaj.art-9eca865fe0ec407388563b1cf17b01b7
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2025-03-14T14:17:26Z
publishDate 2017-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-9eca865fe0ec407388563b1cf17b01b72025-02-27T05:33:14ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01122e017118510.1371/journal.pone.0171185Quantitative liver proteomics identifies FGF19 targets that couple metabolism and proliferation.Vittoria MassafraAlexandra MilonaHarmjan R VosBoudewijn M T BurgeringSaskia W C van MilFibroblast growth factor 19 (FGF19) is a gut-derived peptide hormone that is produced following activation of Farnesoid X Receptor (FXR). FGF19 is secreted and signals to the liver, where it contributes to the homeostasis of bile acid (BA), lipid and carbohydrate metabolism. FGF19 is a promising therapeutic target for the metabolic syndrome and cholestatic diseases, but enthusiasm for its use has been tempered by FGF19-mediated induction of proliferation and hepatocellular carcinoma. To inform future rational design of FGF19-variants, we have conducted temporal quantitative proteomic and gene expression analyses to identify FGF19-targets related to metabolism and proliferation. Mice were fasted for 16 hours, and injected with human FGF19 (1 mg/kg body weight) or vehicle. Liver protein extracts (containing "light" lysine) were mixed 1:1 with a spike-in protein extract from 13C6-lysine metabolically labelled mouse liver (containing "heavy" lysine) and analysed by LC-MS/MS. Our analyses provide a resource of FGF19 target proteins in the liver. 189 proteins were upregulated (≥ 1.5 folds) and 73 proteins were downregulated (≤ -1.5 folds) by FGF19. FGF19 treatment decreased the expression of proteins involved in fatty acid (FA) synthesis, i.e., Fabp5, Scd1, and Acsl3 and increased the expression of Acox1, involved in FA oxidation. As expected, FGF19 increased the expression of proteins known to drive proliferation (i.e., Tgfbi, Vcam1, Anxa2 and Hdlbp). Importantly, many of the FGF19 targets (i.e., Pdk4, Apoa4, Fas and Stat3) have a dual function in both metabolism and cell proliferation. Therefore, our findings challenge the development of FGF19-variants that fully uncouple metabolic benefit from mitogenic potential.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0171185&type=printable
spellingShingle Vittoria Massafra
Alexandra Milona
Harmjan R Vos
Boudewijn M T Burgering
Saskia W C van Mil
Quantitative liver proteomics identifies FGF19 targets that couple metabolism and proliferation.
PLoS ONE
title Quantitative liver proteomics identifies FGF19 targets that couple metabolism and proliferation.
title_full Quantitative liver proteomics identifies FGF19 targets that couple metabolism and proliferation.
title_fullStr Quantitative liver proteomics identifies FGF19 targets that couple metabolism and proliferation.
title_full_unstemmed Quantitative liver proteomics identifies FGF19 targets that couple metabolism and proliferation.
title_short Quantitative liver proteomics identifies FGF19 targets that couple metabolism and proliferation.
title_sort quantitative liver proteomics identifies fgf19 targets that couple metabolism and proliferation
url https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0171185&type=printable
work_keys_str_mv AT vittoriamassafra quantitativeliverproteomicsidentifiesfgf19targetsthatcouplemetabolismandproliferation
AT alexandramilona quantitativeliverproteomicsidentifiesfgf19targetsthatcouplemetabolismandproliferation
AT harmjanrvos quantitativeliverproteomicsidentifiesfgf19targetsthatcouplemetabolismandproliferation
AT boudewijnmtburgering quantitativeliverproteomicsidentifiesfgf19targetsthatcouplemetabolismandproliferation
AT saskiawcvanmil quantitativeliverproteomicsidentifiesfgf19targetsthatcouplemetabolismandproliferation